Introduction
============

Inherited retinal diseases (IRDs) are characterized by a wide spectrum of nonsyndromic and syndromic phenotypes all involving visual impairment.^[@bib1]^ In addition to their clinical heterogeneity, IRDs are characterized by extensive genetic heterogeneity.^[@bib2]^

Despite the large number of identified IRD genes, the genetic basis of IRD remains unknown in 20--50% of cases albeit analyzed by whole-exome sequencing (WES).^[@bib3],\ [@bib4],\ [@bib5]^ Part of the potential missing genetic variation that may be causative for IRD can be attributed to mutations in novel, yet unidentified disease genes.^[@bib6],\ [@bib7]^ It is anticipated that another fraction of unsolved cases can be caused by noncoding sequence variations in known IRD genes, examples of which have been increasingly reported.^[@bib8],\ [@bib9],\ [@bib10]^

Several studies using different approaches demonstrated that structural variations including copy-number variations (CNVs) represent an additional mutation type significantly contributing to the missing genetic variation in IRD.^[@bib11],\ [@bib12],\ [@bib13],\ [@bib14]^ In 2016, Van Cauwenbergh et al. developed a high-resolution array, arrEYE, for targeted CNV analysis of known and candidate IRD genes.^[@bib15]^ Despite different algorithms developed for CNV identification using next-generation sequencing (NGS) data,^[@bib16],\ [@bib17]^ most NGS studies still fail to detect them, leading to an underestimation of CNVs as underlying cause of IRD. Although several IRD genes like *EYS*,^[@bib18]^ *USH2A*,^[@bib19]^ and *PCDH15*^[@bib20]^ are known to be prone to CNV formation, little is known about the contribution of CNVs to IRD in general.

Here, we aimed to identify genomic features that are correlated with CNV occurrence in IRD genes, and to propose a ranking of CNV-prone IRD genes. Furthermore, we demonstrated the efficacy of targeted locus amplification (TLA) for the characterization of complex CNVs on extracted DNA.

Materials and methods
=====================

Literature mining
-----------------

RetNet is a summary of genes that have been associated with isolated and syndromic IRD. An extensive literature mining of virtually all reported CNVs in IRD genes listed in RetNet has been performed by manual text mining ([Supplementary Table S1](#sup1){ref-type="supplementary-material"} and [Supplementary Text S1](#sup1){ref-type="supplementary-material"} online).

Search for CNV-prone IRD genes
------------------------------

The genomic landscape of RetNet genes has been investigated by listing the following genomic features: gene size, number of associated Database of Genomic Variants (DGV) variants,^[@bib21]^ total number of associated repeats, *Alu* repeats, long interspersed nuclear elements (LINE), long terminal repeat elements (LTR), and segmental duplications (SDs), using the UCSC Table Browser ([Supplementary Table S2](#sup1){ref-type="supplementary-material"} and [Supplementary Text S1](#sup1){ref-type="supplementary-material"}).

The rank correlation analysis was performed using the Kendall rank correlation coefficient or tau, which works on ranked, nonparametric data. Calculation of the statistical difference of the values of the different genomic features between the group of genes with one or fewer CNVs and the group of genes with at least two CNVs was performed using a classic *t*-test. Correlations between the different genomic features were calculated using Pearson correlation coefficients ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"} and [Supplementary Text S1](#sup1){ref-type="supplementary-material"}).

CNV analysis in an IRD cohort
-----------------------------

The patient study adhered to the tenets of the Declaration of Helsinki. CNV analysis was performed in a longitudinal way in a diagnostic IRD cohort that underwent different analyses: multiplex ligation-dependent probe amplification (MLPA), arrEYE,^[@bib15]^ single-nucleotide polymorphism (SNP) chip analysis, conventional polymerase chain reaction (PCR) to assess nonamplification and real-time PCR (qPCR). Patients P6, P10, and P11 underwent WES prior to CNV screening. In case of a heterozygous CNV in *USH2A*, the mutation on the second allele was identified by targeted NGS ([Supplementary Text S1](#sup1){ref-type="supplementary-material"}).

Characterization of identified CNVs
-----------------------------------

Based on the genomic coordinates obtained from CNV analysis, further delineation of the breakpoint regions of each CNV was performed by designing conventional PCR or qPCR assays in the breakpoint regions for the homozygous and heterozygous CNVs, respectively, and by performing iterative delineation rounds. When both breakpoint regions were sufficiently delineated, junction PCR was performed by conventional PCR, followed by Sanger sequencing of the junction product ([Supplementary Text S1](#sup1){ref-type="supplementary-material"}).

CNVs with highly repetitive breakpoint regions or for which no specific junction product could be obtained were further delineated using TLA (Cergentis, Utrecht, the Netherlands).^[@bib22]^ For each CNV one or more inverse PCR primers ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}) were designed in a specific anchor region. For a deletion this is the region immediately upstream or downstream of the deletion breakpoints that is not deleted with certainty. For a duplication it is the region close to one of both breakpoints that is duplicated with certainty ([Supplementary Text S1](#sup1){ref-type="supplementary-material"}).

Assessing the underlying mechanisms of the identified CNVs
----------------------------------------------------------

For each CNV that has been delineated at the nucleotide level, an extensive bioinformatics analysis was performed on the breakpoint regions to try to unravel the underlying mechanism, as previously described ([Supplementary Text S1](#sup1){ref-type="supplementary-material"}).^[@bib23]^

Assessing the *cis*-regulatory effect of deleted noncoding elements in the *EYS* and *PCDH15* regions
-----------------------------------------------------------------------------------------------------

To identify putative *cis*-regulatory elements in the *EYS* and *PCDH15* regions, an assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) was performed according to established protocols^[@bib24]^ on adult postmortem human retinal tissue (T.J.C., unpublished data). To determine that transposase-accessible regions represented active promoters or enhancers, chromatin immunoprecipitation with high-throughput sequencing (ChIP-Seq) was performed for the H3K27ac and H3K4me2 histone marks and transcription factors CRX, OTX2, NRL, RORB, and MEF2D using previously described protocols.^[@bib25]^ RNA-seq was performed using standard methods on RNA extracted from nuclei, to enrich for enhancer RNAs ([Supplementary Text S1](#sup1){ref-type="supplementary-material"}).^[@bib26]^

Human *PCDH15*-associated CRX-bound region (CBR) 1 and 2 were PCR amplified from a healthy control individual ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). CBR1 was cloned in a dsRed expressing vector without basal promoter. CBR2 was cloned in another dsRed expressing vector, upstream of a Rho-basal promoter. DNA cocktails containing the *PCDH15* reporter vectors and a pCAG-GFP vector as an electroporation control were coelectroporated into isolated retinas of P0 mice. After 8 days of *in vitro* organ/tissue culture, retinas were harvested, fixed, and imaged. The detailed protocol used for the electroporation assays has been described previously ([Supplementary Text S1](#sup1){ref-type="supplementary-material"}).^[@bib27]^

Results
=======

Mapping the CNV landscape in IRD genes
--------------------------------------

First, we attempted to characterize the CNV landscape in IRD by an exhaustive literature mining of CNVs in all RetNet genes.^[@bib2]^ This revealed 1,345 patients with a reported CNV in one of the known IRD disease genes, more specifically 317 unique CNVs in 81 different genes ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). The discrepancy between the total number of CNVs and the number of unique CNVs can be explained by the presence of common CNVs in certain IRD genes. [Supplementary Table S4](#sup1){ref-type="supplementary-material"} lists the 15 top-ranked genes according to the total CNV count, together with the number of unique CNVs in the corresponding gene. For example, *CLN3* and *NPHP1* have high total but very low unique CNV counts, which can be attributed by a common deletion of exons 7 and 8 of *CLN3*,^[@bib28]^ and a whole-gene deletion of *NPHP1*.^[@bib29],\ [@bib30]^ Apart from genes with common CNVs, several genes like *USH2A*, *OPA1*, and *EYS* are characterized by many different CNVs, contributing to their high CNV load. Finally, *ABCC6* is characterized by both a common exon 23--29 deletion^[@bib31]^ and a high number of other less frequent CNVs.

Mapping the genomic landscape of IRD genes
------------------------------------------

Next, we assessed different genomic features for all RetNet genes ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}).^[@bib2]^ The top-ranked genes according to each of these factors are listed in [Table 1](#tbl1){ref-type="table"}, together with the respective number of CNVs reported in literature and DGV. The output of gene size shows that *EYS*, *PCDH15*, and *USH2A* are the largest IRD genes, which is in agreement with the large number of reported CNVs ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}). While there are large genes for which no disease-related CNVs have been reported up to now, for most of them a significant number of CNVs have been reported in DGV. The other outputs according to the number of total and specific type of repeats in the genomic region are different from the output based on gene size. Although these new top-ranked genes span a smaller genomic region, they contain a higher absolute number of repeats, or are specifically enriched in specific types of repeats.

To assess which of these genomic features could be used to identify and prioritize CNV-prone IRD genes, we first performed a rank correlation analysis, comparing the rank of the genes according to the different genomic features and their respective rank in the literature and DGV lists ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). This revealed that the strongest correlation is obtained for gene size, both according to literature and DGV, followed by LINE and LTR repeats, and total repeats. Importantly, the *Alu* repeats and SDs do not seem to correlate with the number of CNVs. To confirm these results the different IRD genes were divided into two groups based on the absence or presence of at least two CNVs in a gene according to the DGV list. For each of the features we evaluated whether there was a significant difference between the two groups ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). This analysis confirmed the previous results, showing gene size as the feature with the most significant difference between both groups. There was no significant difference in the number of *Alu* repeats and SDs. Finally, we investigated if the different studied genomic features are correlated with each other. This revealed strong correlations of LINE and LTR repeats and total repeats with gene size, while both *Alu* repeats and SDs do not seem to correlate with gene size.

Expanding the CNV mutation spectrum in IRD genes
------------------------------------------------

Apart from the mapping of the CNV spectrum in IRD genes by the literature mining, we expanded the CNV spectrum in IRD by the identification of 30 CNVs in 29 unrelated families, 21 of which are unique and 13 of which are novel ([Table 2](#tbl2){ref-type="table"}).

Patients P6, P10, and P11 underwent WES prior to CNV screening. In P6 this led to the identification of an apparently homozygous nonsense mutation in *MERTK*: c.2323C\>T, p.(Arg775\*). Segregation analysis demonstrated a recessive carrier state in the mother but not in the biologically proven father, indicating pseudohomozygosity. This was confirmed by qPCR analysis, revealing a heterozygous whole-gene deletion of *MERTK* in both the index patient and his father ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). In patients P10 and P11 both arrEYE analysis and WES coverage data analysis revealed two apparently identical homozygous deletions of *PDE6G* ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}). Comparison of SNP chip data in the region surrounding this deletion revealed an identical haplotype in both patients ([Supplementary Table S6](#sup1){ref-type="supplementary-material"}).

The main contribution to the CNVs identified in this study comes from the *USH2A* gene, with 15 CNVs out of 29 patients. For all but one *USH2A*-mutated patients the CNV is heterozygous and the mutation on the second allele was initially identified by targeted NGS. This highlights the importance of CNV screening in patients carrying only one heterozygous pathogenic mutation in disease-associated genes known to harbor mutations inherited under a recessive paradigm, like *USH2A*.

Characterization of identified CNVs and assessment of their underlying mechanisms
---------------------------------------------------------------------------------

All but two of the 21 unique CNVs were further characterized to identify the exact breakpoints. In total, we were able to fully characterize 14 out of 19 investigated CNVs at the nucleotide level ([Table 2](#tbl2){ref-type="table"} and [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). A conventional delineation strategy based on junction PCR led to the complete characterization of eight CNVs at the nucleotide level ([Figure 1](#fig1){ref-type="fig"}), leaving 11 CNVs not fully delineated. The reason for this was the presence of SDs in both breakpoint regions of the *MERTK* deletion, while for the 10 remaining CNVs there were highly repetitive breakpoint regions. For all but one sample we moved on to TLA to further characterize the CNVs in a hypothesis-neutral manner. This approach allowed the identification of the CNV breakpoints in six out of nine patients ([Figure 2](#fig2){ref-type="fig"}), including a more complex CNV in patient P3 ([Figure 3](#fig3){ref-type="fig"}).

In patient P5 conventional mutation screening of *KCNV2* by PCR and Sanger sequencing revealed nonamplification of exon 2, suggesting a homozygous deletion. After delineation of the deletion, segregation analysis was performed in the family using the junction PCR primers. Although both children of the index patient are obligate carriers of this deletion, segregation of the junction product could only be demonstrated in one of the children. Subsequent qPCR of exon 2 of *KCNV2* in the daughter demonstrated a heterozygous deletion of this exon. The most probable explanation for this finding is the occurrence of two different overlapping heterozygous deletions, only one of which was identified by the initial delineation. This was corroborated using qPCR, revealing a second larger deletion overlapping with the smaller one found in the index case and in the daughter ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}).

To unravel the underlying mechanism of the formation of the CNVs identified in this study, a bioinformatics analysis was performed on both breakpoint regions of the 14 molecularly characterized CNVs ([Supplementary Table S7](#sup1){ref-type="supplementary-material"}). Short stretches of microhomology (1--3 bp) were identified at eight CNV junctions. Three CNVs showed a perfect transition at their junction, accompanied by an insertion of seven nucleotides for one of them. The three remaining CNVs display more complex insertions, which can be explained by multiple iterative template switches based on short stretches of microhomology ([Figure 3](#fig3){ref-type="fig"}).^[@bib32]^ None of the CNVs has similar repetitive elements in the corresponding breakpoint regions, except for the *MERTK* deletion, where the presence of SDs points to nonallelic homologous recombination (NAHR) as a surmised underlying mechanism. The presence of previously described structural variation--associated sequence motifs in all studied breakpoint regions can result in genomic instability and facilitate the formation of CNVs.^[@bib32],\ [@bib33]^ Visualization of microhomology and repetitive elements and an overview of the identified sequence motifs can be found in [Supplementary Figures S5--S7](#sup1){ref-type="supplementary-material"}.

Assessing the effect of noncoding CNVs in the *EYS* and *PCDH15* loci
---------------------------------------------------------------------

Three CNVs were found in noncoding regions: two involving the promoter region and the first exon of *EYS* (P4) and *PCDH15* (P9), respectively, previously reported as pathogenic CNVs.^[@bib20],\ [@bib34]^ The third homozygous CNV is located 214 kb upstream of *EYS* (P3). In order to assess a potential regulatory effect on their neighboring genes, a *cis*-regulatory data set was evaluated for the *PCDH15* and *EYS* loci in human adult retina. For the promoter deletions of *EYS* (P4) and *PCDH15* (P9), several *cis*-regulatory elements coincide with the CNVs, likely being disrupted by the deletions and affecting gene expression. For the complex CNV upstream of *EYS* (P3), no *cis*-regulatory, epigenomic marks could be identified in the CNV region.

The potential regulatory effect of the large upstream deletion of *PCDH15* (P9) was further investigated by electroporation assays in mouse retinal explants. The deleted region harbors two CBRs, one partially overlapping with the first noncoding exon and included in the promoter region of the gene (CBR1), the other one located approximately 100 kb upstream (CBR2) ([Figure 1](#fig1){ref-type="fig"}). Therefore, the human CBR1 sequence was cloned immediately upstream of the dsRed reporter gene, while CBR2 was cloned upstream of a dsRed reporter gene carrying a minimal basal promoter. Electroporation of both constructs in mouse retinal explants demonstrated *cis*-regulatory activity of CBR2, while CBR1 seems to fail in driving dsRed expression on its own ([Figure 1](#fig1){ref-type="fig"}).

Discussion
==========

Exploring the CNV and genomic landscape of IRD genes reveals CNV-prone IRD genes
--------------------------------------------------------------------------------

The major aim of this study was to map the genomic landscape of IRD genes in order to prioritize those genes prone to CNVs. We conducted an extensive literature mining of reported CNVs in all known IRD genes listed in RetNet and retrieved 1,345 CNVs in 81 different genes from 300 different publications, more than half of which were published in the past six years.

We investigated genomic features of all known IRD disease genes to find susceptibility factors for CNV formation and to establish rankings of CNV-prone IRD genes ([Table 1](#tbl1){ref-type="table"}). The correlation between gene size and number of repeats is reflected by the presence of large genes such as *EYS*, *PCDH15*, and *USH2A* in the different rankings. Interestingly, in the output of the number of associated repeats, several genes such as *CLN3*, *CRX*, *PNPLA6*, and *FAM161A* can be found at a considerably higher position compared to the output list of gene size, meaning that they are located in genomic regions highly enriched with repeats. Because *Alu* repeat density has previously been associated with recurrent exonic loss^[@bib35]^ and nonrecurrent intragenic deletions,^[@bib36]^ this specific type of repeat was also taken into account. Based on this output, genes such as *ZNF408*, *CLUAP1*, *ROM1*, and *PRPF8* have the largest increase in rank compared with gene ranking based on total number of associated repeats and have high *Alu* repeat percentages. As NAHR between low-copy repeats such as SDs is an important mechanism of recurrent genomic rearrangements,^[@bib32]^ the presence of SDs was also assessed, resulting in many highly ranked genes not present in the other outputs. As expected, several of these genes, like *NPHP1*, *CA4*, *BBS4*, *CIB2*, *CDHR1*, *RGR*, and *CNNM4* overlap with the NAHR-prone regions proposed by Bujakowska et al. in 2016.^[@bib13]^ Finally, the occurrence of LINE and LTR repeats was investigated, as they also have the potential to mediate NAHR,^[@bib37],\ [@bib38]^ leading to a list of genes highly similar to the gene size output.

Correlation analysis demonstrated that gene size has the strongest correlation with the presence of a CNV in that specific gene, followed by the number of associated LINE and LTR repeats and the number of total repeats. However, these last two features are both highly correlated with gene size. Although *Alu* repeats and SDs have been shown to play a role in the formation of CNVs,^[@bib32]^ the presence of these repeats does not seem to correlate with the occurrence of CNVs. The absence of a significant association of CNVs with *Alu* repeats was previously proposed, suggesting that *Alu* elements do not currently play an important role in the formation of CNVs, while they did so in the past. This is supported by the observation of highly significant colocalization of older SDs, which can be seen as fixed CNVs in the population, with *Alu* repeats, while this correlation is decreasing rapidly for younger SDs and is totally absent for CNVs. This study also demonstrated that CNVs co-occur with SDs, but that the correlation is much smaller than may be expected, suggesting an important contribution of other mechanisms in the formation of CNVs.^[@bib39]^

We correlated the results of the literature mining to the output list of CNV-prone IRD disease genes and found discrepancies for genes for which no associated CNVs could be found in literature, despite a high number of CNVs in DGV. One possible explanation may be that a CNV in an IRD gene leading to loss of function is not necessarily pathogenic, while a dominant pathogenic missense mutation in the same gene causing a gain of function has a pathogenic effect. In addition, some of these genes have been discovered only recently as IRD genes, and are less prevalent in the context of IRD. A last and important reason is that CNV screening has not been routinely implemented, likely leading to an underestimation of the CNV mutational load in these genes. In this respect, the occurrence of CNVs could be expected in *ADAMTS18*, *CERKL*, *CNGB3*, *CRB1*, *DHDDS*, *FAM161A*, and *IMPG1*, as they are highly ranked as CNV-prone genes according to gene size or total repeats and as mutations in these genes are well known causes of IRD. In order to increase CNV detection in a clinical setting, we recommend performing routine targeted CNV screening in the most prevalent 30 top-ranked IRD genes according to genomic length, such as *EYS*, *PCDH15*, *USH2A*, *CDH23*, *ALMS1*, *CRB1*, *CNGB3*, and *CHM*, especially for monoallelic patients in case of autosomal recessive inheritance. The latter statement is corroborated by the high percentage of CNVs (i.e., 30% 15/50) in the monoallelic *USH2A* cohort of IRD patients screened in the current study.

Expanding the CNV mutation spectrum in IRD genes
------------------------------------------------

The proposed list of CNV-prone IRD genes was further validated by the identification of 21 different CNVs in 29 families, affecting 10 different genes. The initial CNV analyses in this study were performed in subcohorts with IRD, rather than in one general IRD cohort. Therefore, the denominators for these different subcohorts with IRD are the following: (i) heterozygous CNVs in patients with vitelliform macular dystrophy screened for *BEST1* mutations by sequencing of the coding region and MLPA (2/140; 1.4%); (ii) heterozygous CNVs in patients with optic atrophy screened for *OPA1* mutations by sequencing of the coding region and MLPA (2/234; 0.43%); (iii) heterozygous CNVs in IRD cases with monoallelic *USH2A* mutation, identified by MLPA (15/50; 30%); and (iv) homozygous CNVs identified by homozygosity mapping in an IRD cohort of consanguineous origin (6/99; 6%).

It is striking that most CNVs were found in *USH2A*, which is the third largest IRD gene. Other genes that are highly ranked according to gene size are *EYS*, *MERTK*, *OPA1*, and *PCDH15*. Moreover, *MERTK* is located in one of the recently identified NAHR-prone regions.^[@bib13]^ *PRPH2* and *PDE6G* are smaller genes, but highly enriched in *Alu* repeats. CNVs in *BEST1*, *PRPH2*, and *SPATA7* have previously been described only once,^[@bib40],\ [@bib41],\ [@bib42]^ and for *PDE6G* this is the first CNV reported in IRD. To the best of our knowledge, this is the second *PDE6G* genetic defect reported in IRD after the initial identification as an IRD gene.^[@bib43]^

Interestingly, we found two cases of pseudohomozygosity in two different nonconsanguineous families: a homozygous nonsense mutation in *MERTK* c.2323C\>T, p.(Arg775\*) in an arRP family and a homozygous exon 2 deletion of *KCNV2* in a family with arCRD. In the first family we found a heterozygous whole-gene deletion of *MERTK*, overlapping with the nonsense mutation. In the second family we showed two different overlapping heterozygous *KCNV2* deletions. These cases of pseudohomozygosity illustrate the importance of segregation analysis, CNV screening, and delineation in patients with apparent homozygous mutations without consanguineous background.

Apart from 18 coding CNVs, we identified three CNVs located in noncoding regions. Two of these are a deletion of the first noncoding exon and the associated promoter region of *EYS* and *PCDH15*, respectively, most probably affecting transcription by the disruption of retina-specific *cis*-regulatory elements. This was supported by integration with a *cis*-regulatory data set generated in human adult retina and by *in vivo* studies in mouse retinal explants. For the third noncoding deletion there is no evidence for overlap with any of the retina-specific *cis*-regulatory elements. According to DGV, several CNVs overlap with this region, as is the case for the rest of the *EYS* gene, including the coding parts. Altogether, although we could not provide evidence for a pathogenic effect of this CNV, an effect on the chromatin conformation of the *EYS* region and on *EYS* transcription cannot be excluded.

Characterization of CNVs in a hypothesis-neutral manner and identification of replicative mechanisms as major underlying contributor
------------------------------------------------------------------------------------------------------------------------------------

As the CNV identification study was performed in a longitudinal setting, different targeted CNV analysis strategies were used, including a customized microarray.^[@bib15]^ Several recent studies have reported WES as a tool to identify both homozygous and heterozygous CNVs in IRD.^[@bib11],\ [@bib44],\ [@bib45]^ Exact delineation of the CNVs using this approach is not possible, however, which can be overcome by the use of WGS.^[@bib9],\ [@bib14],\ [@bib46]^

Apart from the conventional delineation strategies, we introduced TLA on extracted genomic DNA to characterize CNVs. Indeed, TLA has recently been described as a strategy to selectively amplify and sequence entire genetic loci on the basis of the crosslinking of physically proximal sequences.^[@bib22]^ Advantage of the technique is that no detailed prior locus information is needed, as is the case for other targeted approaches. TLA has previously been shown to be effective when applied on living cells, while here, we demonstrated for the first time its efficacy on extracted human DNA.

In addition to the *MERTK* deletion that arose through NAHR of SDs located in both breakpoint regions, the detailed bioinformatics analyses performed for all delineated CNVs revealed three different groups according to putative underlying molecular mechanisms. The largest group consisting of eight CNVs with short stretches of microhomology may be explained by nonhomologous end joining or a replicative-based repair mechanism like microhomology-mediated break-induced replication, favoring the latter because an information scar, typical of nonhomologous end joining, was absent in all CNVs.^[@bib32]^ Remarkably, the formation of the *PDE6G* CNVs identified in this study was not mediated by the presence of *Alu* repeats in the breakpoint regions, although this gene has the second highest *Alu* repeat percentage of all RetNet genes. The second group comprises three CNVs with no reported microhomology, and the presence of an information scar for one of them, pointing towards nonhomologous end joining as underlying mechanism. Finally, the last three CNVs are associated with more complex insertions, characterized by microhomology at all breakpoint junctions and most probably caused by microhomology-mediated break-induced replication, which has been proposed as the major mechanism for nonrecurrent structural variations.^[@bib32]^ These results put replicative-based repair mechanisms forward as a major underlying contributor of the CNVs identified in this study.

General conclusion and perspectives
-----------------------------------

This comprehensive study investigated the role of CNVs in IRD. We mapped and correlated the CNV and genomic landscape of 256 IRD genes, revealing genomic features that point to CNV risk. We expanded the CNV mutation spectrum in IRD genes, characterized the identified CNVs in a hypothesis-neutral manner, and assessed their underlying mechanisms. Our study demonstrates the importance of the CNV mutational load in IRD and contributes to the elucidation of the hidden genetic variation in IRD. It will be useful for the interpretation of CNV data in future genomic studies of IRD. Finally, this IRD-oriented CNV study can be extrapolated to other genetically heterogeneous Mendelian diseases with hidden genetic variation.
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![**Identification and characterization of a noncoding** ***PCDH15*** **deletion.** (**a**) Location of the deletion. The homozygous 1.3-Mb deletion identified in P9 is depicted in red, removing the first noncoding exon of the *PCDH15* gene, the *MTRNR2L5* gene with unknown function and two *PCDH15*-associated CRX-bound regions (CBR). CBR1 is situated in the promoter region, while CBR2 is located approximately 100 kb upstream. (**b**) Delineation of the deletion. Further refinement of the deletion breakpoint regions by conventional PCR. Black, orange and blue shaded boxes and connecting lines indicate nondeleted exon and introns, deleted exon, intron and upstream region, and nondeleted upstream region, respectively. Short grey horizontal lines correspond to designed PCR amplicons, used to delineate the deletion. The black dotted line indicates the junction product. (**c**) Sanger sequencing of the junction product. Delineation of the deletion at the nucleotide level, chr10: g.56478660_57777934del. (**d**) Electroporation assays. In order to assess the *cis*-regulatory effect of CBR1 and CBR2, electroporation reporter assays were performed in mouse retinal explants. The first construct consisted of CBR2 cloned in a dsRed expressing vector, upstream of a Rho-basal promoter, as CBR2 is located in a more distant regulatory region. For the second construct, CBR1 was cloned in a dsRed expressing vector without basal promoter, as it is located in the promoter region. *Cis*-regulatory activity could be demonstrated for the CBR2 construct, while CBR1 seems to fail in driving dsRed expression on its own. (**e**) *Cis*-regulatory landscape of *PCDH15*. Epigenomic marks and transcription factor binding were assessed in human adult retina, shown here for the *PCDH15* locus: ATAC-seq; ChIP-seq for H3K27ac, H3K4me2, CRX, OTX2, NRL, RORB and MEF2D; and RNA-seq. The region of the deletion is marked with a shaded rectangle and the putative active promoter and enhancer regions included in the deleted region are in lighter shading.](gim201797f1){#fig1}

![**Identification and characterization of a** ***BEST1*** **deletion using targeted locus amplification (TLA) on extracted genomic DNA.** (**a**) Location of the deletion. The heterozygous 8-kb deletion identified in P1 is depicted in red, removing the first two exons of the *BEST1* gene. (**b**) Primer design TLA. Initial real-time polymerase chain reaction (qPCR) delineation of the deletion was hampered by highly repetitive breakpoint regions, followed by further delineation using TLA. The minimal deleted region based on the qPCR delineation is depicted in red; the gray dotted line corresponds to the 5′ and 3′ breakpoint regions and the surrounding genomic region in black. In case of a deletion, the outward-oriented TLA primers indicated in orange need to be designed in an anchor region that is not deleted, here in the downstream surrounding genomic region. (**c**) TLA read mapping. The amplified PCR products are sequenced by next-generation sequencing (NGS), followed by mapping of the resulting reads showing one distinct peak surrounding the anchor region. (**d**) Delineation of the deletion. Detailed analysis of the reads in the breakpoint regions led to the identification of the deletion at nucleotide level: chr11:g.61711373_61719810del. The upper, middle, and lower lines represent the sequences of the 5′ wild-type (wt) region, the deletion junction product, and the 3′ wt region, respectively. Microhomology of 3 bp is indicated in gray. The two boxes show the mapped reads in both breakpoint regions. Green sequences are forward reads; red sequences are reverse reads. The fully colored reads are wt reads, while the reads containing shaded sequences are junction reads spanning the deletion breakpoints. The turquoise and orange boxes highlight the 5′ and 3′ sequences, separated by the 3 bp of microhomology.](gim201797f2){#fig2}

![**Identification and characterization of a complex noncoding** ***EYS*****deletion using targeted locus amplification (TLA).** (**a**) Location of the deletion. The homozygous 16-kb deletion identified in P3 is depicted in red, located upstream of the *EYS* gene. (**b**) Delineation of complex deletion. Due to problems using conventional polymerase chain reaction (PCR) as an initial delineation strategy, TLA was used for further characterization of the deletion at nucleotide level. Analysis of the resulting TLA reads revealed a complex copy-number variation (CNV) consisting of a deletion of chr6: 66,631,318-66,647,641 (hatched region), together with an insertion of a 455-bp fragment consisting of a 277-bp sequence (chr6: 66,628,168-66,628,444) located upstream of the deletion (turquoise region) joined to an inverted 178-bp fragment (chr6: 66,642,009-66,642,186) situated in the deleted region (orange region). The upper part of the figure represents the wt sequence, while the lower part shows the resulting mutated sequence. The underlying mutational mechanism, represented in the middle part, is most probably a replication-based mechanism. The numbers correspond to different template switches, based on the observed microhomology in every breakpoint region. (**c**) Microhomology at the breakpoints. Comparison of the sequences at the three breakpoint junctions shows microhomology at every junction, supporting microhomology-mediated break-induced replication as the underlying mechanism. (**d**) *Cis*-regulatory landscape of *EYS*. Epigenomic marks and transcription factor binding were assessed in human adult retina, shown here for the upstream *EYS* region: ATAC-seq; ChIP-seq for H3K27ac, H3K4me2, CRX, OTX2, NRL, RORB and MEF2D; and RNA-seq. The region of the deletion is marked with a shaded rectangle and the putative active promoter and enhancer region included in the deleted region are in lighter shading, for both the deletion presented in this figure (insertions/inversion indicated by black vertical lines) and another regulatory *EYS* deletion identified in P2. For the latter, both the promoter and an enhancer region coincide with the CNV, whereas for the complex CNV no *cis*-regulatory epigenomic marks could be seen in the affected region.](gim201797f3){#fig3}

###### Ranking of genomic landscape of IRD genes according to gene size, number of total associated repeats, *Alu* repeats, LINE and LTR repeats, and segmental duplications, together with the number of CNVs according to literature and DGV

  **Gene size**   **Total repeats**   ***Alu* repeats**   **LINE and LTR repeats**   **Segmental duplications**                                                                                 
  --------------- ------------------- ------------------- -------------------------- ---------------------------- ------- ------------ ----- ------ ----------- ---- ------- ------------ ----- -------
  *EYS*           24                  9,470               *EYS*                      24                           9,470   *OPA3*       0     27     *EYS*       24   9,470   *HMX1*       0     10
  *PCDH15*        15                  6,344               *PCDH15*                   15                           6,344   *NMNAT1*     2     1      *PCDH15*    15   6,344   *CLN3*       515   18
  *USH2A*         57                  598                 *WDPCP*                    0                            174     *CLN3*       515   18     *WDPCP*     0    174     *NPHP1*      75    445
  *WDPCP*         0                   174                 *ADGRV1*                   4                            192     *PRPF8*      0     6      *USH2A*     57   598     *CA4*        0     10
  *ADGRV1*        4                   192                 *CDH23*                    3                            740     *CTNNA1*     0     117    *ADGRV1*    4    192     *SDCCAG8*    1     123
  *RIMS1*         0                   1945                *USH2A*                    57                           598     *PCYT1A*     0     420    *BBS9*      7    897     *ABCC6*      235   141
  *BBS9*          7                   897                 *BBS9*                     7                            897     *PNPLA6*     0     3      *NBAS*      0    59      *OPN1SW*     0     100
  *HMCN1*         0                   723                 *ZNF423*                   0                            287     *CRX*        1     60     *RIMS1*     0    1,945   *BBS4*       13    10
  *CDH23*         3                   740                 *CTNNA1*                   0                            117     *PRPF3*      0     3      *INVS*      0    53      *IMPDH1*     0     24
  *NBAS*          0                   59                  *OPA3*                     0                            27      *CDH3*       1     44     *ALMS1*     5    73      *ACBD5*      0     8
  *ZNF423*        0                   287                 *CRX*                      1                            60      *C12ORF65*   0     6      *HMCN1*     0    723     *GPR179*     0     2
  *CTNNA1*        0                   117                 *TTLL5*                    0                            404     *DHDDS*      0     11     *GPR125*    0    143     *CIB2*       0     7
  *TTLL5*         0                   404                 *NBAS*                     0                            59      *RAX2*       0     2      *TEAD1*     0    148     *ADIPOR1*    0     0
  *TEAD1*         0                   148                 *CLN3*                     515                          18      *ROM1*       0     6      *ZNF423*    0    287     *TRPM1*      7     77
  *SDCCAG8*       1                   123                 *ABCC6*                    235                          141     *PRPH2*      1     4      *TTLL5*     0    404     *PCDH15*     15    6,344
  *COL11A1*       7                   60                  *HK1*                      0                            113     *CEP250*     0     4      *CDH23*     3    740     *RGS9*       0     2
  *ALMS1*         5                   73                  *CDH3*                     1                            44      *FAM161A*    0     13     *PLA2G5*    0    77      *RBP3*       0     24
  *AHI1*          1                   96                  *KIAA1549*                 0                            69      *ARL3*       0     2      *CC2D2A*    1    149     *LCA5*       1     8
  *CRB1*          0                   43                  *DHDDS*                    0                            11      *ABCC6*      235   141    *CTNNA1*    0    117     *SLC24A1*    0     3
  *INVS*          0                   53                  *DFNB31*                   0                            53      *KIF11*      0     5      *MYO7A*     6    85      *CRB1*       0     43
  *ATF6*          0                   43                  *PCYT1A*                   0                            420     *PRCD*       0     6      *ATF6*      0    43      *NR2F1*      3     21
  *CNGB3*         0                   45                  *RIMS1*                    0                            1,945   *ZNF408*     0     0      *CNGB3*     0    45      *CDHR1*      0     3
  *ADAMTS18*      0                   40                  *HMCN1*                    0                            723     *RPGRIP1*    1     2547   *KIZ*       0    120     *RGR*        0     4
  *CHM*           30                  435                 *PDE6A*                    1                            45      *CLUAP1*     0     2      *TRPM1*     7    77      *CSPP1*      0     55
  *LAMA1*         1                   55                  *INVS*                     0                            53      *SEMA4A*     0     1      *PITPNM3*   0    20      *POMGNT1*    0     19
  *GPR125*        0                   143                 *KIF11*                    0                            5       *KIAA1549*   0     69     *TTC8*      0    20      *PRPF6*      0     67
  *TRPM1*         7                   77                  *PNPLA6*                   0                            3       *NYX*        5     5      *MERTK*     7    90      *PCYT1A*     0     420
  *IMPG1*         0                   88                  *FAM161A*                  0                            13      *GPR179*     0     2      *PROM1*     0    7       *NPHP4*      1     163
  *KIAA1549*      0                   69                  *ALMS1*                    5                            73      *HK1*        0     113    *CEP290*    2    10      *CNNM4*      2     171
  *CERKL*         0                   55                  *CEP250*                   0                            4       *BBS1*       6     4      *CAPN5*     1    56      *RPGRIP1L*   0     145

CNV, copy-number variation; DGV, respective number of CNVs according to the Database of Genomic Variants; IRD, inherited retinal diseases; LINE, long interspersed nuclear elements; Lit., respective absolute number of CNVs in patients with IRD according to literature; LTR, long terminal repeat elements.

###### Overview of CNVs identified in this study

  **Patient**   **Gene**       **CNV type**   **Zygosity**   **Clinical diagnosis**   **Exons**           **Allele 1**                                                        **Allele 2**                                                        **Detection method**   **Delineation method**   **Genomic coordinates at nt level**                                                                        **Segregation**   **Reference**
  ------------- -------------- -------------- -------------- ------------------------ ------------------- ------------------------------------------------------------------- ------------------------------------------------------------------- ---------------------- ------------------------ ---------------------------------------------------------------------------------------------------------- ----------------- ----------------
  P1            ***BEST1***    **Del**        **Het**        **arB**                  **E1-2 (fs)**       **c.-580-5983_152+380del**                                          **NA**                                                              **MLPA**               **TLA**                  **chr11:g.61711373_61719810del**                                                                           **No**            **This study**
  P2            ***BEST1***    **Del**        **Het**        **adBMD**                **E1-2 (fs)**       **c.-580-5983_152+380del**                                          **NA**                                                              **MLPA**               **TLA**                  **chr11:g.61711373_61719810del**                                                                           **Yes**           **This study**
  P3            ***EYS***      **Del**        **Hom**        **arRP**                 **Upstream (NC)**   **Upstream deletion + complex insertion**                           **Upstream deletion + complex insertion**                           **SNP chip**           **TLA**                  **chr6: g.66631318_66647641del + ins of chr6: 66628168_66628444 + ins of chr6: 66642009_66642186 (inv)**   **Yes**           **This study**
  P4            *EYS*          Del            Hom            arRP                     E1 (NC)             c.-538-?\_-448+?del                                                 c.-538-?\_-448+?del                                                 SNP chip               TLA                      ?                                                                                                          Yes               Ref. [@bib34]
  P5            ***KCNV2***    **Del**        **Het**        **arCRD**                **E2 (end)**        **c.1356+4642\_\*37095del**                                         **c.1357-5153_1638+897del**                                         **PCR**                **PCR**                  **chr9: g.2723737_2766822del**                                                                             **Yes**           **This study**
  P5            ***KCNV2***    **Del**        **Het**        **arCRD**                **E2 (end)**        **c.1357-5153\_\*897del**                                           **c.1356+4642_1638+37095del**                                       **PCR**                **PCR**                  **chr9: g.2724293_2730624del**                                                                             **Yes**           **This study**
  P6            ***MERTK***    **Del**        **Het**        **arRP**                 **E1- 19 (WG)**     **c.1-?\_\*504+?del**                                               **c.2323C\>T, p.(Arg775\*) (ExAC MAF: 0.00082%)**                   **qPCR**               **NA**                   **?**                                                                                                      **Yes**           **This study**
  P7            ***OPA1***     **Dup**        **Het**        **adOPA**                **E6-27 (fs)**      **c.625-?\_2818+?dup**                                              **NA**                                                              **MLPA**               **TLA**                  **?**                                                                                                      **No**            **This study**
  **P8**        *OPA1*         Del            Het            adOPA                    E1-29 (WG)          c.1-?\_\*3211+**?**del                                              NA                                                                  MLPA                   NA                       **?**                                                                                                      No                PMID: 17306754
  **P9**        *PCDH15*       Del            Hom            arRP                     E1 (NC)             c.-395-1216883\_-28-54604del                                        c.-395-1216883\_-28-54604del                                        SNP chip               PCR                      chr10: g.56478660_57777934del                                                                              No                Ref. [@bib20]
  P10           ***PDE6G***    **Del**        **Hom**        **arRP**                 **E3-4 (end)**      **NM_001290212.1(TSPAN10):c.658_NM_002602.3(PDE6G):c.147-456del**   **NM_001290212.1(TSPAN10):c.658_NM_002602.3(PDE6G):c.147-456del**   **arrEYE**             **PCR**                  **chr17: g.79612525_79619171del**                                                                          **No**            **This study**
  P11           ***PDE6G***    **Del**        **Hom**        **arRP**                 **E3-4 (end)**      **NM_001290212.1(TSPAN10):c.658_NM_002602.3(PDE6G):c.147-456del**   **NM_001290212.1(TSPAN10):c.658_NM_002602.3(PDE6G):c.147-456del**   **arrEYE**             **PCR**                  **chr17: g.79612525_79619171del**                                                                          **No**            **This study**
  P12           ***PRPH2***    **Del**        **Het**        **adMD**                 **E3 (end)**        **c.829-?\_\*1700+?del**                                            **NA**                                                              **MLPA**               **NA**                   **?**                                                                                                      **No**            **This study**
  P13           ***PRPH2***    **Del**        **Het**        **adMD**                 **E1-3 (WG)**       **c.1-26916\_\*34871delinsTATTTTT**                                 **NA**                                                              **MLPA**               **TLA**                  **chr6:g.42631162_42716988delinsTATTTTT**                                                                  **Yes**           **This study**
  P14           ***SPATA7***   **Del**        **Hom**        **arLCA**                **E1-4 (fs)**       **c.1-7152_239-734del+c.239-729_239-721dup**                        **c.1-7152_239-734del+c.239-729_239-721dup**                        **PCR**                **TLA**                  **chr14: g.88845011_88882321del + chr14: g.88882326_88882334dup**                                          **Yes**           **This study**
  P15           ***USH2A***    **Del**        **Het**        **arUS**                 **E3 (fs)**         **c.486-1344_651+2629del**                                          **c.2299del, p.(Glu767Serfs\*21) (ExAC MAF: 0.079%)**               **MLPA**               **PCR**                  **chr1: g.216589227_216593365del**                                                                         **No**            **This study**
  **P16**       *USH2A*        Dup            Het            arUS                     E4-13 (fs)          c.652-23900_2809+1417dupinsTTACTTGATTATTACTG                        c.2276G\>T, p.(Cys759Phe) (ExAC MAF : 0.078%)                       MLPA                   TLA                      chr1: g.216418510_216562327dupinsTTACTTGATTATTACTG                                                         Yes               Ref. [@bib19]
  **P17**       *USH2A*        Dup            Het            arRP                     E4-13 (fs)          c.652-23900_2809+1417dupinsTTACTTGATTATTACTG                        c.2276G\>T, p.(Cys759Phe) (ExAC MAF : 0.078%)                       MLPA                   TLA                      chr1: g.216418510_216562327dupinsTTACTTGATTATTACTG                                                         No                Ref. [@bib19]
  **P18**       *USH2A*        Dup            Het            arUS                     E4-13 (fs)          c.652-23900_2809+1417dupinsTTACTTGATTATTACTG                        c.2209C\>T, p.(Arg737\*) (ExAC MAF : 0.00083%)                      MLPA                   TLA                      chr1: g.216418510_216562327dupinsTTACTTGATTATTACTG                                                         No                Ref. [@bib19]
  **P19**       *USH2A*        Dup            Het            arUS                     E4-13 (fs)          c.652-23900_2809+1417dupinsTTACTTGATTATTACTG                        c.6587G\>C, p.(Ser2196Thr) (ExAC MAF: 1.15%, benign)                MLPA                   TLA                      chr1: g.216418510_216562327dupinsTTACTTGATTATTACTG                                                         No                Ref. [@bib19]
  **P20**       *USH2A*        Dup            Het            arRP                     E4-13 (fs)          c.652-23900_2809+1417dupinsTTACTTGATTATTACTG                        c.2276G\>T, p.(Cys759Phe) (ExAC MAF : 0.078%)                       MLPA                   TLA                      chr1: g.216418510_216562327dupinsTTACTTGATTATTACTG                                                         No                Ref. [@bib19]
  **P21**       *USH2A*        Del            Hom            arUS                     E5-10 (if)          c.785-6636_1840+208del                                              c.785-6636_1840+208del                                              MLPA                   PCR                      chr1: g.216465309_216507632del                                                                             No                PMID: 24944099
  P22           ***USH2A***    **Del**        **Het**        **arUS**                 **E12-13 (fs)**     **c.1972-10840_2809+4440del**                                       **c.2299del, p.(Glu767Serfs\*21)** **(ExAC MAF: 0.079%)**           **MLPA**               **PCR**                  **chr1: g.216415487_216435280del**                                                                         **Yes**           **This study**
  **P23**       *USH2A*        Del            Het            arUS                     E22 (fs)            c.4628-**?**\_4758+**?**del                                         c.8167C\>T, p.(Arg2723\*) (ExAC MAF: 0.00082%)                      MLPA                   NA                       ?                                                                                                          No                PMID: 25558175
  **P24**       *USH2A*        Del            Het            arUS                     E22-24 (if)         c.4627+25434_4987+657del                                            c.14587G\>T, p.(Glu4863\*) (not present in ExAC)                    MLPA                   TLA                      chr1: g.216259404_216323160del                                                                             No                PMID: 25804404
  **P25**       *USH2A*        Del            Het            arUS                     E44 (fs)            c.8682-1666_8845+139del                                             c.10689T\>A, p.(Tyr3563\*) (not present in ExAC)                    MLPA                   PCR                      chr1: g.216040210_216042178del                                                                             No                PMID: 25404053
  **P26**       *USH2A*        Del            Het            arUS                     E44 (fs)            c.8682-1666_8845+139del                                             c.921_922insCAGC (ExAC MAF: 0.011%)                                 MLPA                   PCR                      chr1: g.216040210_216042178del                                                                             No                PMID: 25404053
  P27           ***USH2A***    **Dup**        **Het**        **arUS**                 **E62 (if)**        **c.12067-?\_12294+?dup**                                           **c.653T\>A, p.(Val218Glu)** **(ExAC MAF: 0.0041%)**                **MLPA**               **TLA**                  **?**                                                                                                      **No**            **This study**
  P28           ***USH2A***    **Dup**        **Het**        **arUS**                 **E62 (if)**        **c.12067-?\_12294+?dup**                                           **c.1256G\>T, p.(Cys419Phe)** **(ExAC MAF: 0.0051%)**               **MLPA**               **TLA**                  **?**                                                                                                      **No**            **This study**
  P29           ***USH2A***    **Dup**        **Het**        **arUS**                 **E62 (if)**        **c.12067-?\_12294+?dup**                                           **c.11864G\>A, p.(Trp3955\*)** **(ExAC MAF: 0.011%)**               **MLPA**               **TLA**                  **?**                                                                                                      **No**            **This study**

ad, autosomal dominant; ar, autosomal recessive; B, bestrophinopathy; BMD, Best macular dystrophy; CNV, copy-number variation; CRD, cone rod dystrophy; Del, deletion; Dup, duplication; end, CNV extends until 3′ UTR; fs, frameshift; Het, heterozygous; Hom, homozygous; if, in-frame; LCA, Leber congenital amaurosis; MAF, minor allele frequency; MD, macular dystrophy; MLPA, multiplex ligation-dependent probe amplification; NC, noncoding; nt, nucleotide; OPA, optic atrophy; PCR, polymerase chain reaction; qPCR, quantitative PCR; RP, retinitis pigmentosa; SNP, single-nucleotide polymorphism; TLA, targeted locus amplification; US, Usher syndrome; UTR, untranslated region; WG, whole gene.

This table presents an overview of the different CNVs identified in this study, novel CNVs are indicated in bold. The "Exons" column shows which exons of the gene are affected by the CNV and shows whether the change is in-frame, causes a frameshift, affects the end of the gene including the 3′ UTR, is noncoding, or encompasses the whole gene. Most of the CNVs have been picked up by MLPA (P1, P2, P7, P8, P12, P13, P15--29); two are found using arrEYE (P10, P11), an in-house developed customized microarray (Van Cauwenbergh et al. 2016); three have been identified by SNP chip analysis in consanguineous families (P3, P4, P9); one homozygous deletion (P14) and another apparently homozygous deletion (P5, which later turned out to be two different overlapping heterozygous deletions) have been discovered by nonamplification when performing conventional PCR; and the presence of a last heterozygous CNV has been demonstrated by qPCR (P6). Apart from conventional PCR, targeted locus amplification (TLA) has been used to delineate the CNVs at nucleotide level. The last column shows whether the identified CNVs are novel or have been previously published. Novelty has been assessed based on exon level, not on nucleotide level. The variant identified in P19 in addition to the *USH2A* CNV is predicted to be benign and has a high MAF (\>1%). This patient carries either a second yet unidentified *USH2A* mutation, or is a heterozygous carrier of the *USH2A* CNV and has another underlying disease gene.

Reference sequences: *BEST1*: NM_004183.3, *EYS*: NM_001292009.1, *KCNV2*: NM_133497.3, *MERTK*: NM_006343.2, *OPA1*: NM_015560.2, *PCDH15*: NM_033056.3, *PDE6G*: NM_002602.3, *PRPH2*: NM_000322.4, *SPATA7*: NM_018418.4, *USH2A*: NM_206933.2.
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